Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Billings Clinic - Downtown
1345
mi
from 43215
Billings, MT
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Billings Clinic - Downtown
1345
mi
from 43215
Billings, MT
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Montana Cancer Specialists at Montana Cancer Center
1614
mi
from 43215
Missoula, MT
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Montana Cancer Specialists at Montana Cancer Center
1614
mi
from 43215
Missoula, MT
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Good Samaritan Hospital
65
mi
from 43215
Dayton, OH
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Good Samaritan Hospital
65
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
CCOP - Dayton
63
mi
from 43215
Dayton, OH
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
CCOP - Dayton
63
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Charles F. Kettering Memorial Hospital
63
mi
from 43215
Kettering, OH
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Charles F. Kettering Memorial Hospital
63
mi
from 43215
Kettering, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
St. Charles Mercy Hospital
118
mi
from 43215
Oregon, OH
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
St. Charles Mercy Hospital
118
mi
from 43215
Oregon, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
St. Vincent Mercy Medical Center
121
mi
from 43215
Toledo, OH
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
St. Vincent Mercy Medical Center
121
mi
from 43215
Toledo, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Medical University of Ohio Cancer Center
117
mi
from 43215
Toledo, OH
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Medical University of Ohio Cancer Center
117
mi
from 43215
Toledo, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
CCOP - Toledo Community Hospital
120
mi
from 43215
Toledo, OH
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
CCOP - Toledo Community Hospital
120
mi
from 43215
Toledo, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Sanford Cancer Center at Sanford USD Medical Center
747
mi
from 43215
Sioux Falls, SD
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Sanford Cancer Center at Sanford USD Medical Center
747
mi
from 43215
Sioux Falls, SD
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Fredericksburg Oncology, Incorporated
319
mi
from 43215
Fredericksburg, VA
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Fredericksburg Oncology, Incorporated
319
mi
from 43215
Fredericksburg, VA
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
403
mi
from 43215
Green Bay, WI
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
403
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Green Bay Oncology, Limited at St. Mary's Hospital
407
mi
from 43215
Green Bay, WI
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Green Bay Oncology, Limited at St. Mary's Hospital
407
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
St. Mary's Hospital Medical Center - Green Bay
407
mi
from 43215
Green Bay, WI
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
St. Mary's Hospital Medical Center - Green Bay
407
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Green Bay Oncology, Limited - Oconto Falls
427
mi
from 43215
Oconto Falls, WI
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Green Bay Oncology, Limited - Oconto Falls
427
mi
from 43215
Oconto Falls, WI
Click here to add this to my saved trials
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated:  8/11/2016
Green Bay Oncology, Limited - Sturgeon Bay
405
mi
from 43215
Sturgeon Bay, WI
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
Status: Enrolling
Updated: 8/11/2016
Green Bay Oncology, Limited - Sturgeon Bay
405
mi
from 43215
Sturgeon Bay, WI
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
624
mi
from 43215
Little Rock, AR
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
624
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
East Bay Radiation Oncology Center
2090
mi
from 43215
Castro Valley, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
East Bay Radiation Oncology Center
2090
mi
from 43215
Castro Valley, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Valley Medical Oncology Consultants - Castro Valley
2090
mi
from 43215
Castro Valley, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Valley Medical Oncology Consultants - Castro Valley
2090
mi
from 43215
Castro Valley, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Valley Medical Oncology
2088
mi
from 43215
Fremont, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Valley Medical Oncology
2088
mi
from 43215
Fremont, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Contra Costa Regional Medical Center
2087
mi
from 43215
Martinez, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Contra Costa Regional Medical Center
2087
mi
from 43215
Martinez, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
El Camino Hospital Cancer Center
2097
mi
from 43215
Mountain View, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
El Camino Hospital Cancer Center
2097
mi
from 43215
Mountain View, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Alta Bates Summit Medical Center - Summit Campus
2098
mi
from 43215
Oakland, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Alta Bates Summit Medical Center - Summit Campus
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Bay Area Breast Surgeons, Incorporated
2098
mi
from 43215
Oakland, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Bay Area Breast Surgeons, Incorporated
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
CCOP - Bay Area Tumor Institute
2098
mi
from 43215
Oakland, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
CCOP - Bay Area Tumor Institute
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Highland General Hospital
2095
mi
from 43215
Oakland, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Highland General Hospital
2095
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Epic Care - Oakland
2099
mi
from 43215
Oakland, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Epic Care - Oakland
2099
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Tom K Lee, Incorporated
2098
mi
from 43215
Oakland, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Tom K Lee, Incorporated
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Doctors Medical Center - San Pablo Campus
2099
mi
from 43215
San Pablo, CA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Doctors Medical Center - San Pablo Campus
2099
mi
from 43215
San Pablo, CA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
554
mi
from 43215
Hartford, CT
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
554
mi
from 43215
Hartford, CT
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
547
mi
from 43215
New Britain, CT
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
547
mi
from 43215
New Britain, CT
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
1715
mi
from 43215
Boise, ID
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
1715
mi
from 43215
Boise, ID
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
St. Joseph Regional Medical Center
1754
mi
from 43215
Lewiston, ID
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
St. Joseph Regional Medical Center
1754
mi
from 43215
Lewiston, ID
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
CCOP - Carle Cancer Center
274
mi
from 43215
Urbana, IL
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
CCOP - Carle Cancer Center
274
mi
from 43215
Urbana, IL
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Michiana Hematology-Oncology
195
mi
from 43215
Elkhart, IN
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Michiana Hematology-Oncology
195
mi
from 43215
Elkhart, IN
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Elkhart General Hospital
191
mi
from 43215
Elkhart, IN
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Elkhart General Hospital
191
mi
from 43215
Elkhart, IN
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Elkhart Clinic, LLC
195
mi
from 43215
Elkhart, IN
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Elkhart Clinic, LLC
195
mi
from 43215
Elkhart, IN
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Fort Wayne Medical Oncology and Hematology
137
mi
from 43215
Fort Wayne, IN
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Fort Wayne Medical Oncology and Hematology
137
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Center for Cancer Therapy at LaPorte Hospital and Health Services
224
mi
from 43215
La Porte, IN
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Center for Cancer Therapy at LaPorte Hospital and Health Services
224
mi
from 43215
La Porte, IN
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Saint Anthony Memorial Health Centers
234
mi
from 43215
Michigan City, IN
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Saint Anthony Memorial Health Centers
234
mi
from 43215
Michigan City, IN
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Saint Joseph Regional Medical Center
202
mi
from 43215
Mishawaka, IN
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Saint Joseph Regional Medical Center
202
mi
from 43215
Mishawaka, IN
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Michiana Hematology Oncology
197
mi
from 43215
Plymouth, IN
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Michiana Hematology Oncology
197
mi
from 43215
Plymouth, IN
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Memorial Hospital of South Bend
205
mi
from 43215
South Bend, IN
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Memorial Hospital of South Bend
205
mi
from 43215
South Bend, IN
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Mercy Regional Cancer Center at Mercy Medical Center
469
mi
from 43215
Cedar Rapids, IA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Mercy Regional Cancer Center at Mercy Medical Center
469
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Cedar Rapids Oncology Associates
469
mi
from 43215
Cedar Rapids, IA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Cedar Rapids Oncology Associates
469
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
565
mi
from 43215
Des Moines, IA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
Mercy Cancer Center - West Lakes
573
mi
from 43215
Clive, IA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
Mercy Cancer Center - West Lakes
573
mi
from 43215
Clive, IA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
John Stoddard Cancer Center at Iowa Methodist Medical Center
565
mi
from 43215
Des Moines, IA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
John Stoddard Cancer Center at Iowa Methodist Medical Center
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  8/11/2016
CCOP - Iowa Oncology Research Association
565
mi
from 43215
Des Moines, IA
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 8/11/2016
CCOP - Iowa Oncology Research Association
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials